MedTrace Logo

Immediate Postoperative Bevacizumab Administration in Proliferative Diabetic Retinopathy Patients Undergoing Vitrectomy

NCT06899529 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2025-03-28

No results posted yet for this study

Summary

Patients undergoing surgery for complications related to diabetes will be recruited.

Conditions

  • Proliferative Diabetic Retinopathy - High Risk

Interventions

PROCEDURE

Bevacizumab

Bevacizumab will be given immediately after surgery in the Treatment Group

Sponsors & Collaborators

  • Christian Ophthalmic Surgery Expedition Network

    lead OTHER

Principal Investigators

  • Isaac Aleman, MD · Christian Ophthalmic Surgery Expedition Network

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-20
Primary Completion
2027-03-20
Completion
2027-05-20

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06899529 on ClinicalTrials.gov